CHDI
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease
Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif., Dec. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercis ...Read More
13th Annual HD Therapeutics Conference
CHDI is delighted to announce that the 13th Annual HD Therapeutics Conference will be held February 26-March 1, 2018, in Palm Springs, California. The conference program is currently being crafted and will cover all aspects of drug discovery related ...Read More
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide
TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Path), ...Read More
HudsonAlpha and CHDI Foundation announce Huntington disease collaboration
Project will study gene regulatory network of genetic neurodegenerative disorder Huntsville, Ala. — HudsonAlpha Institute for Biotechnology ...Read More
Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington’s Disease Completed and Open-Label Extension Study to Open in 2H 2017
CARLSBAD, Calif., June 22, 2017 -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients ...Read More
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
VY-HTT01 Selection Based on Robust Knockdown of Huntingtin in Preclinical Studies Program On Track for IND Filing in 2018
Cambridge, Mass., June 1, 2017 – Voyager Therapeutics, I ...Read More12th Annual HD Therapeutics Conference
Coming soon… online hosting of the presentations from the Malta conference. ...Read More
Critical Path Institute and CHDI Foundation, Inc. establish a consortium to expedite approval of Huntington’s disease therapeutics
TUCSON, Arizona, October 31, 2016 — Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly ...Read More
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS) today announced a researc ...Read More